{"entity":{"id":"nct07341100","kind":"trial","name":"Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC","aka":[],"tldr":"A phase 2 trial of SKB264 in ovarian cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., active and no longer recruiting.","summary":"Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC is a phase 2 interventional study registered as NCT07341100 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 20 participants enrolled, started 2026-01-16 and due to reach its primary completion in 2028-01. Interventions recorded: SKB264 and Clarithromycin.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07341100","url":"https://clinicaltrials.gov/study/NCT07341100"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["kelun-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07341100","phase":"2","setting":"A Multicenter, Open-label Clinical Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin, a Potent CYP3A Inhibitor, on the Pharmacokinetics of SKB264 in Patients With Ovarian Epithelial Cancer","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","enrolled":20,"outcomes":[]},"route":"/trials/nct07341100/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"company":[{"id":"kelun-biotech","kind":"company","name":"Sichuan Kelun-Biotech","route":"/companies/kelun-biotech/"}]}}